Grant Clive S, Ingle James N, Suman Vera J, Dumesic Daniel A, Wickerham D Lawrence, Gelber Richard D, Flynn Patrick J, Weir Lorna M, Intra Mattia, Jones Wayne O, Perez Edith A, Hartmann Lynn C
Division of General Surgery, Mayo Clinic, North Central Cancer Treatment Group, Dept of Surgery, 200 1st St SW, Rochester, MN 55905, USA.
J Clin Oncol. 2009 Aug 1;27(22):3620-6. doi: 10.1200/JCO.2008.21.3603. Epub 2009 Jun 1.
For nearly two decades, multiple retrospective reports, small prospective studies, and meta-analyses have arrived at conflicting results regarding the value of timing surgical intervention for breast cancer on the basis of menstrual cycle phase. We present the results of a multi-cooperative group, prospective, observational trial of menstrual cycle phase and outcome after breast cancer surgery, led by the North Central Cancer Treatment Group (NCCTG) in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the International Breast Cancer Study Group (IBCSG).
Premenopausal women age 18 to 55 years, who were interviewed for menstrual history and who were surgically treated for stages I to II breast cancer, had serum drawn within 1 day of surgery for estradiol, progesterone, and luteinizing hormone levels. Menstrual history and hormone levels were used to determine menstrual phase: luteal, follicular, and other. Disease-free survival (DFS) and overall survival (OS) rates were determined by Kaplan-Meier method and were compared by using the log-rank test and Cox proportional hazard modeling.
Of 1,118 women initially enrolled, 834 women comprised the study cohort: 230 (28%) in luteal phase; 363 (44%) in follicular phase; and 241 grouped as other. During a median follow-up of 6.6 years, and in analysis that accounted for nodal disease, estrogen receptor status, adjuvant radiation therapy or chemotherapy, neither DFS nor OS differed with respect to menstrual phase. The 5-year DFS rates were 82.7%, 82.1%, and 79.2% for follicular, luteal, or other phases, respectively. Corresponding OS survival rates were 91.9%, 92.2%, and 91.8%, respectively.
When menstrual cycle phases were strictly defined, neither DFS nor OS differed between women who underwent surgery during the follicular phase versus the luteal phase. Nearly 30% of the patients did not meet criteria for either follicular- or luteal-phase categories.
近二十年来,多项回顾性报告、小型前瞻性研究及荟萃分析,在基于月经周期阶段进行乳腺癌手术干预的时机价值方面得出了相互矛盾的结果。我们展示了一项由北中部癌症治疗组(NCCTG)与国家乳腺与肠道外科辅助治疗项目(NSABP)及国际乳腺癌研究组(IBCSG)合作开展的多协作组前瞻性观察性试验的结果,该试验涉及月经周期阶段与乳腺癌手术后的结局。
年龄在18至55岁的绝经前女性,接受了月经史访谈,并接受了I至II期乳腺癌的手术治疗,在手术1天内采集血清以检测雌二醇、孕酮和促黄体生成素水平。月经史和激素水平用于确定月经周期阶段:黄体期、卵泡期及其他。无病生存率(DFS)和总生存率(OS)采用Kaplan-Meier法确定,并通过对数秩检验和Cox比例风险模型进行比较。
最初纳入的1118名女性中,834名女性组成了研究队列:230名(28%)处于黄体期;363名(44%)处于卵泡期;241名归为其他。在中位随访6.6年期间,在考虑淋巴结疾病、雌激素受体状态、辅助放疗或化疗的分析中,DFS和OS在月经周期阶段方面均无差异。卵泡期、黄体期或其他阶段的5年DFS率分别为82.7%、82.1%和79.2%。相应的OS生存率分别为91.9%、92.2%和91.8%。
当严格定义月经周期阶段时,在卵泡期与黄体期接受手术的女性之间,DFS和OS均无差异。近30%的患者不符合卵泡期或黄体期分类标准。